PLAT and benign prostatic hyperplasia: Hence, due to this variability, the only notable quantifiable difference in TPα expression across the “PCRC TMA” was a modest but significant increase between the benign versus all Gleason groupings (Benign/BPH versus Gleason 3/4/5; P = 0.024; Figure 2A).